Health Topics — Gut Health
CBG and Inflammatory Bowel Disease: What Research Has Found
The most direct preclinical evidence for CBG in gut inflammation comes from a 2013 mouse model study — what it found, why a mouse model of colitis is not human IBD, and what the result does and doesn't tell us.
Procedural Note
Inflammatory bowel disease — including Crohn's disease and ulcerative colitis — is a serious chronic condition managed under gastroenterologist care. Established pharmaceutical and biological treatments exist and are effective for many patients. This article discusses preclinical research only. Nothing here constitutes guidance on managing IBD or any of its symptoms. People with IBD should work with their gastroenterologist on treatment decisions.
Of all the conditions examined in CBG's preclinical research portfolio, inflammatory bowel disease has the most directly relevant animal model evidence. The 2013 Borrelli study is not perfect — no animal model is — but it examined CBG directly, in a living animal system, in a model designed to approximate human gut inflammation. Reading it carefully is worth the effort.
What IBD Is and Why the Gut's Immune System Is Central
Inflammatory bowel disease — IBD — is an umbrella term for two distinct chronic inflammatory conditions of the gastrointestinal tract: Crohn's disease, which can affect any part of the digestive tract from mouth to rectum in a discontinuous pattern, and ulcerative colitis, which affects the colon and rectum in a continuous pattern confined to the mucosal lining. Both involve chronic, dysregulated immune activation in the gut wall — the immune system mounting an inflammatory response against gut contents or gut bacteria that, in a healthy person, would be tolerated without reaction.
The gut contains the largest immune compartment in the body — gut-associated lymphoid tissue (GALT) — because the digestive tract faces the constant challenge of distinguishing harmful pathogens from harmless food antigens and the trillions of commensal bacteria that make up the microbiome. In IBD, this distinction fails or is lost. The resulting chronic inflammation causes mucosal damage, ulceration, barrier breakdown, and in Crohn's disease, transmural involvement that can lead to fistulas, strictures, and abscesses. Symptomatically, IBD produces abdominal pain, diarrhea (often bloody in ulcerative colitis), weight loss, fatigue, and systemic inflammatory effects extending well beyond the gut.
The ECS in Gut Inflammation — Why CBG Is a Research Target
CB2 receptors — the cannabinoid receptor type concentrated in immune tissue — are expressed throughout the gut's immune compartment and are significantly upregulated in the inflamed gut tissue of IBD patients compared to healthy controls. This upregulation pattern is consistent with CB2's documented role in modulating inflammatory immune responses: the receptor appears to be part of the body's own attempt to regulate the inflammatory process, and its elevated expression in active IBD suggests it is being activated in response to ongoing inflammation.
The Borrelli Study — Design and Findings
Model: DNBS-induced colitis in mice. DNBS (dinitrobenzene sulfonic acid) is a chemical agent instilled directly into the colon that triggers an acute inflammatory response mimicking some features of Crohn's disease — mucosal damage, immune cell infiltration, elevated inflammatory cytokines, and increased gut permeability. It is a well-established and widely used IBD model, though it produces acute chemical colitis rather than the chronic, relapsing-remitting inflammatory pattern characteristic of human IBD.
CBG Administration: CBG was administered at doses of 1, 5, and 10 mg/kg intraperitoneally — injected directly into the abdominal cavity, not taken orally. This route of administration provides high bioavailability and precise dosing but does not reflect the oral or sublingual administration routes relevant to consumer use. Dose-dependent effects were observed across the range tested.
Primary Findings: CBG-treated mice showed significantly reduced macroscopic colon damage scores compared to vehicle-treated controls — meaning the visible damage to the colon lining was measurably less severe. Histological examination confirmed reduced immune cell infiltration into the colon wall, reduced mucosal damage depth, and preservation of colon architecture. Inflammatory marker analysis showed reduced iNOS expression, reduced nitric oxide production, and reduced levels of pro-inflammatory cytokines including IL-1β and TNF-α in colon tissue.
Mechanism Identified: Mechanistic analysis pointed to PPAR-γ activation as a primary contributor to CBG's anti-inflammatory effects in this model. When a PPAR-γ antagonist was co-administered with CBG, the protective effects were substantially reduced — providing evidence that PPAR-γ activation was causally involved, not merely correlational. CB2 agonism and iNOS inhibition were identified as additional contributing mechanisms.
What the Study Establishes: CBG produces measurable anti-inflammatory effects in a mouse model of acute chemical colitis, operating through at least three documented mechanisms: PPAR-γ activation, CB2 partial agonism, and iNOS inhibition. This is a genuine, directly relevant preclinical finding using CBG itself — not a derivative compound. It is the strongest direct animal model evidence for CBG's gut anti-inflammatory activity in the archive.
Reading the Model Honestly
The DNBS model is a legitimate and informative preclinical tool. It is also meaningfully different from human IBD in several ways that matter for interpretation.
DNBS-induced colitis is acute and chemically triggered — it produces a rapid inflammatory response over days, resolves if the animal survives, and does not reproduce the chronic, immune-mediated, genetically influenced disease course of Crohn's or ulcerative colitis in humans. Human IBD involves complex interactions between genetic susceptibility, the gut microbiome, mucosal immune dysregulation, and environmental triggers that play out over years and decades. The mouse gut immune system, while broadly homologous to the human gut immune system, differs in important ways — particularly in the relative proportions and functions of immune cell populations.
The intraperitoneal route of administration in the Borrelli study is another important distinction. Oral bioavailability of CBG is substantially lower and more variable than intraperitoneal injection. The doses producing effects in the study (1–10 mg/kg IP) do not directly translate to human oral doses. How CBG reaches gut tissue in meaningful concentrations following oral administration — and at what dose — has not been studied in humans.
The Human Trial Gap — Stated Plainly
No human clinical trial has examined CBG specifically for inflammatory bowel disease as of 2026. The broader cannabis and IBD clinical trial literature — examining THC- and CBD-containing preparations — has produced mixed results, with some signal for symptom relief (pain, nausea, appetite) and inconsistent evidence for actual mucosal healing or disease modification. CBG's preclinical profile is mechanistically distinct from THC and has specific features — PPAR-γ agonism, CB2 partial agonism, iNOS inhibition — that are relevant to IBD pathology. Whether those features translate to meaningful clinical benefit in people with Crohn's or ulcerative colitis has not been tested.
The Honest Evidence Summary
The Borrelli 2013 study is the best direct evidence for CBG's gut anti-inflammatory activity in the archive. It used CBG itself (not a derivative), in a living animal system, in a relevant disease model, and identified multiple contributing mechanisms including a causal PPAR-γ finding via antagonist co-administration. That is a genuinely informative preclinical study.
It is one mouse model of acute chemical colitis. Human IBD is a chronic, complex, immune-mediated disease. No human trial data exists for CBG in IBD. People managing Crohn's disease or ulcerative colitis under medical care should make treatment decisions with their gastroenterologist, not on the basis of preclinical animal research however promising its mechanistic profile.
References
- Borrelli, F., Fasolino, I., Romano, B., et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316.
- Borrelli, F., Aviello, G., Romano, B., et al. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine, 87(11), 1111–1121.
- Izzo, A.A., & Sharkey, K.A. (2010). Cannabinoids and the gut: New developments and emerging concepts. Pharmacology & Therapeutics, 126(1), 21–38.
- Naftali, T., Bar-Lev Schleider, L., Dotan, I., et al. (2013). Cannabis induces a clinical response in patients with Crohn's disease: A prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 11(10), 1276–1280.
- Sharkey, K.A., & Wiley, J.W. (2016). The role of the endocannabinoid system in the brain-gut axis. Gastroenterology, 151(2), 252–266.
- Storr, M.A., Keenan, C.M., Bhargava, A., et al. (2009). Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammation, 32(4), 222–231.
- Vézina, C.M., & Bhargava, A. (2017). CB2 cannabinoid receptor agonists as therapeutic targets for inflammatory bowel disease. Expert Opinion on Therapeutic Targets, 21(9), 887–897.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.